TFF Pharmaceuticals Announces Oral Presentation Of Interim Data From The Phase 2 Study Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection At The 44th Annual ISHLT 2024 Meeting

Author: Benzinga Newsdesk | March 25, 2024 09:16am

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024. On January 9, 2024, the Company announced that the data from TFF TAC Phase 2 study was accepted as a late-breaking abstract.   

 

"Results from the ongoing Phase 2 trial of TFF TAC continue to suggest that targeted, inhalational delivery of tacrolimus has the potential to provide sufficient immunosuppression to avoid acute rejection at diminished systemic exposures compared to oral tacrolimus" said Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital and Lead Principal Investigator of the Phase 2 TFF TAC trial. "Based on interim clinical data, TFF TAC appears to have the potential to provide a meaningful advancement in the delivery of immunosuppression therapy, and I look forward to presenting updated data from the Phase 2 trial at the upcoming ISHLT 2024 meeting."

Presentation Details:

Control Number:	5349
Abstract Title:	Multicenter Open-Label Tacrolimus Inhalation Powder Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics (pk) in Lung Transplant (ltx)  Recipients with Significant Renal Impairment
Presenter:	Professor Gregory Snell
Session:	ORAL SESS 39
Date/Time:	Saturday, April 13, 2024, 8:00 – 9:15 AM CEST

 

Posted In: TFFP